Introduction {#Sec1}
============

Type 2 diabetes (T2D) poses an enormous socio-economic burden \[[@CR1]\]. It is associated with numerous vascular complications and a three- to sixfold increase in cardiovascular disease (CVD) risk. Optimising blood glucose levels remains a primary therapeutic target \[[@CR2]\]. Despite modest effects, lifestyle modification incorporating diet and exercise remains the cornerstone of T2D management \[[@CR2]--[@CR6]\]. Lifestyle modification and particularly a low-carbohydrate diet can improve glycaemic control \[[@CR7], [@CR8]\] including reducing a patient's glycaemic variability (GV), i.e. the oscillations in blood glucose levels throughout the day \[[@CR9]\]. GV has been identified as an independent risk factor for diabetes complications including CVD \[[@CR1], [@CR10]--[@CR14]\]. Despite strong efficacy of lifestyle modification programmes, their effectiveness is often underpinned by intensive techniques requiring close monitoring and health professionals' support to achieve adherence and desired health outcomes \[[@CR15]\]. These practice models are therefore resource-intensive and cost-prohibitive, limiting their widespread availability.

Self-regulation that enables a patient to exert confidence and control over their diet and exercise behaviours is a key component to effective lifestyle intervention adherence \[[@CR16], [@CR17]\]. One approach to enhance patient self-regulation is to provide them with immediate feedback based on the results of their behaviours \[[@CR18]\]. Self-monitoring of health markers and behaviours beyond the clinical setting has been used as an effective tool to monitor treatment response and improve adherence for a variety of health outcomes including body weight, blood pressure and physical activity \[[@CR18]\]. This suggests that self-monitoring of blood glucose (SMBG) in T2D could serve as an immediate feedback function to provide patients with evidence of the biological effect of lifestyle choices on blood glucose levels that may improve adherence to lifestyle prescription and improve glycaemic outcomes \[[@CR19]--[@CR21]\]. Real-time continuous glucose monitoring (RT-CGM), which provides an ongoing display of glucose levels over an extended period (i.e. days/weeks), allows an individual to self-monitor how their blood glucose level responds to various lifestyle factors including diet and exercise, with direct and continuous dynamic feedback. It is therefore possible that RT-CGM might motivate and guide patients to adapt their lifestyle patterns in an appropriate manner to reduce GV and improve glycaemic control. Previous studies have shown that RT-CGM can promote an approximately 0.5% (absolute) greater reduction in HbA1c compared to conventional SMBG using the finger-prick method in T2D \[[@CR20], [@CR22]--[@CR25]\]. However, these studies did not comprehensively assess the effects of RT-CGM on GV or combine this therapeutic strategy within a comprehensive and structured diet and lifestyle programme that targets minimisation of wide glucose fluctuations. Consequently, previous studies have required patients to make changes to diet and exercise in response to SMBG in the absence of advice on those changes that will be most effective to optimise glycaemic control. The purpose of this feasibility study was to examine the effects of RT-CGM compared to blinded CGM on blood glucose control as assessed by HbA1c, GV and CVD risk markers when undertaking a prescriptive lifestyle modification programme that has minimal healthcare practitioner involvement.

Methods {#Sec2}
=======

Study Participants {#Sec3}
------------------

Twenty adults who were overweight or obese (BMI 26--45 kg/m^2^, age 20--75 years) with T2D \[HbA1c 5.9--6.9% (41.0--51.9 mmol/mol)\] were recruited via public advertisement to participate in a randomised controlled study, conducted between June and September 2017 at the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Health and Nutrition Research Unit (Adelaide Australia), Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"} (participant flow). Exclusion criteria were type 1 diabetes; proteinuria (urinary albumin-to-creatinine ratio ≥ 30 mg/mmol), abnormal liver function \[alanine aminotransferase (ALT), aspartate aminotransferase (AST) or gamma-glutamyl transferase (GGT) ≥ 2.5 times the normal upper limit\], impaired renal function (eGFR \< 60 ml/min), any abnormal or significant clinical history including current malignancy, liver, respiratory, gastrointestinal, cardiovascular disease or pregnancy/lactation, eating disorder or clinical depression; any significant endocrinopathy (other than stable treated thyroid disease); have taken/or taking glucocorticoids (oral/inhaled or topical) within last 3 months, psychotropics other than a stable dose of a selective serotonin reuptake inhibitor; illicit drugs, medications which affect gastrointestinal motility or hunger/appetite (e.g. metoclopramide, domperidone and cisapride, anticholinergic drugs (e.g. atropine), erythromycin) or past history of gastrointestinal surgery which may affect study outcomes. All participants provided written informed consent prior to participation. The study was registered with the Australian New Zealand Clinical Trials Registry (ANZTR 372898) and approved by the Human Research Ethics Committees of the CSIRO and the University of Adelaide.Table 1Changes in primary and secondary outcome profiles during the study and comparisons between treatmentsVariableRT-CGM (*n* = 10)Blinded CGM (*n* = 10)*P* value (ANCOVA)Baseline12 weeksChangeBaseline12 weeksChangeGlycaemic control HbA1c (%)6.60 ± 0.865.90 ± 0.57− 0.67 ± 0.827.11 ± 0.806.43 ± 0.92− 0.68 ± 0.740.43 MeS^a^1.01 ± 1.080.71 ± 0.72− 0.30 ± 0.591.19 ± 1.021.21 ± 0.980.02 ± 0.230.110Body weight and composition Weight (kg)101.26 ± 15.0393.85 ± 15.59− 7.41 ± 4.5092.94 ± 15.5187.49 ± 16.75− 5.45 ± 4.030.307 Muscle mass (kg)33.36 ± 6.0732.79 ± 6.34− 0.58 ± 0.9532.43 ± 7.1631.88 ± 7.44− 0.55 ± 0.860.881 Body fat (kg)41.75 ± 11.2935.18 ± 11.34− 6.57 ± 4.0535.11 ± 6.2130.51 ± 5.79− 4.60 ± 3.270.455 Body fat (%)40.80 ± 7.6037.00 ± 8.58− 3.80 ± 3.1638.5 ± 5.4635.1 ± 3.90− 3.40 ± 2.950.904 Fat free mass (kg)59.5 ± 10.2458.67 ± 10.65− 0.84 ± 1.5557.83 ± 11.9056.98 ± 12.29− 0.85 ± 1.380.956 Lean trunk mass (kg)28.07 ± 4.4126.97 ± 4.78− 1.10 ± 1.1627.33 ± 5.1426.49 ± 5.43− 0.84 ± 0.890.533 Fat trunk mass (kg)21.50 ± 4.5318.40 ± 5.23− 3.10 ± 2.4318.93 ± 3.4516.59 ± 3.38− 2.34 ± 1.710.524Cardiovascular risk markers Fasting glucose (mmol/L)7.44 ± 1.356.27 ± 1.42− 1.17 ± 1.948.74 ± 1.927.77 ± 1.86− 0.97 ± 2.200.146 Fasting insulin (mU/L)19.19 ± 8.6514.93 ± 9.12− 4.26 ± 5.9120.23 ± 7.3717.77 ± 6.76− 2.46 ± 5.730.419 Fasting insulin (pmol/L)132.26 ± 60.04103.68 ± 63.37− 29.58 ± 41.08140.49 ± 51.16123.40 ± 46.93− 17.08 ± 39.820.419 Serum TC (mmol/L)4.33 ± 1.324.29 ± 1.25− 0.04 ± 0.383.67 ± 0.493.41 ± 0.40− 0.26 ± 0.520.123 Serum LDL-C^b^ (mmol/L)2.53 ± 1.082.46 ± 1.02− 0.07 ± 0.342.15 ± 0.411.89 ± 0.38− 0.26 ± 0.420.152 Serum HDL-C (mmol/L)1.34 ± 0.161.41 ± 0.190.07 ± 0.261.10 ± 0.341.17 ± 0.360.07 ± 0.090.619 Serum TAG (mmol/L)1.62 ± 0.651.30 ± 0.76− 0.32 ± 0.461.65 ± 0.721.29 ± 0.45− 0.36 ± 0.530.884 Mean diastolic blood pressure (mg/Hg)76.70 ± 9.7675.53 ± 8.00− 1.67 ± 7.2476.87 ± 8.7071.80 ± 7.42− 5.07 ± 6.280.152 Mean systolic blood pressure (mg/Hg)133.40 ± 22.50130.03 ± 12.79− 3.37 ± 17.71130.93 ± 8.38120.70 ± 11.10− 10.23 ± 12.960.099Physical activity (accelerometry) (9 intervention, 10 control) % (Mean daily) time spent in sedentary behaviour87.4 ± 4.984.2 ± 5.8− 3.2 ± 2.288.4 ± 4.686.5 ± 4.7− 2.0 ± 1.70.329 % (Mean daily) time spent in moderate/vigorous activity3.9 ± 2.25.4 ± 3.41.5 ± 1.83.3 ± 2.13.8 ± 2.30.5 ± 0.50.114All values are mean ± SD unless otherwise stated. ANCOVA analysis was used to compare the change in each of the outcome measures at week 12, between the 2 groups using baseline measures as covariatesTotal analysed *n* = 20 (RT-CGM 10, blinded CGM 10) unless otherwise stated*RT-CGM* real-time continuous glucose monitoring, *Blinded CGM* blinded continuous glucose monitoring, *HbA1c*% glycated haemoglobin, *MeS* medication effect score, *IQR* interquartile range (median), *TC* total cholesterol, *LDL-C* low-density lipoprotein cholesterol, *HDL-C* high-density lipoprotein cholesterol, *TAG* triacylglycerol^a^Analyses were performed on natural log (MeS + 0.1) (*P* values), raw data reported^b^Analyses were performed on natural log transformed data (*P* values), raw data reported Fig. 1Participant flow

Study Design and Intervention {#Sec4}
-----------------------------

This was a feasibility pilot study, i.e. a small-scale investigation that was conducted and published to inform researchers of important parameters and sample size requirements required for an adequately powered randomised control trial. In a parallel design, participants were matched for age and gender and randomised using a computer-generated randomisation procedure ([www.randomisation.com](http://www.randomisation.com)) to undertake a 12-week lifestyle (diet and exercise) intervention with either (1) real-time continuous glucose monitoring (RT-CGM) with access to visual display or (2) continuous glucose monitoring (blinded CGM; control), with no access to visual display. Randomisation (sequence generation) was performed by the clinical trials manager, who was unblinded for the purpose of providing device and technology support, including technical troubleshooting for device connectivity and the administration of sensor kits to the participants. All other research associates responsible for data collection, processing and analysis were blinded until data analysis was complete. Participants received a once-off honorarium (\$200 AUD) for trial participation.

At week 0 (after the completion of baseline assessments), participants in both groups received a prescriptive low-carbohydrate, high-protein and unsaturated fat diet (LC diet) and exercise plan, incorporating moderate intensity aerobic/resistance exercises in the form of a commercial publication; at this point randomisation was revealed to participants and to primary staff responsible for administration of glucose sensors and downloads \[[@CR26]\]. The dietary prescription had a planned macronutrient profile of 14% of total energy as carbohydrate, 28% protein and 58% total fat (35% monounsaturated fat), individualised for energy level based on achieving a 30% energy restriction. This dietary profile and lifestyle programme have been previously demonstrated to promote weight loss and enhance glycaemic control and cardiovascular disease risk markers \[[@CR7], [@CR8]\]. At week 3, participants were provided with education on food exchanges and provided lists of alternative foods, based on similar nutrient and energy density of foods within the dietary benchmarks, to assist participants with making suitable food substitutions to improve their dietary flexibility. Use of the materials was self-regulated. Participants received no further formal lifestyle counselling regarding the diet and exercise plan.

Both groups were instructed to perform usual SMBG readings before and after each meal and at bedtime, as per standard practice. Blood glucose monitoring logs were kept and participants were provided with glucometers and testing strips to promote compliance. To facilitate compliance with CGM device wear, at commencement of the study, participants met with a research nurse and dietitian who provided training with practice demonstrations on how insert, initiate, calibrate and change the glucose sensor every 10 days over the 12-week period. Contact details for the research nurse were provided to participants for remote device support and to answer any queries on insertion, initiation and changing of the sensor during the intervention. Participants visited the clinic every 3 weeks for the research nurse to download sensor glucose data, check on glucose sensor insertion and initiation technique, review morning fasting glucose logs, and to replenish devices supplies.

Outcome Measures {#Sec5}
----------------

Outcomes were assessed at baseline (week 0) and end of intervention (week 12). The primary outcomes were HbA1c (Clinpath, Adelaide, Australia), diurnal GV \[[@CR7], [@CR27]\] and diabetes-related medication changes assessed by the anti-glycaemic medication effect score (MeS) \[[@CR7], [@CR28], [@CR29]\]. The anti-glycaemic medication effect score is an overall assessment of the total use of anti-glycaemic agents, based on type and dose of agents, with the high scores corresponding to higher anti-glycaemic medication usage. This calculation takes into consideration each prescribed drug by daily patient dose and is expressed as a percentage of maximum recommended daily dose of that drug. This percentage is then multiplied by an adjustment factor, e.g. 1.5 for sulfonylureas and biguanides and 2.5 for insulin. For individuals prescribed more than one anti-glycaemic agent, each agent's daily dose is multiplied by the respective adjustment factor and outcomes aggregated to generate the final MeS \[[@CR28]--[@CR30]\]. For example, at baseline one participant was prescribed 1000 mg and 500 mg of an oral hypoglycaemic agent, metformin, in the morning and night, respectively, for a total daily dose of 1500 mg. Maximum daily dose for this medication is 3000 mg, and therefore the participant's dose for this medication was 50%. This value is then multiplied by the relevant drug's adjustment factor, 1.5 in this example, providing an overall baseline MeS of 0.75. At trial completion (week 12), this participant had experienced a dose reduction in metformin to 500 mg twice daily resulting in a total daily dose of 1000 mg (33% of the drugs maximum daily dose) and a MeS of 0.50. To determine the change in the MeS (and medication intensity), the post-study MeS (0.50) is subtracted from baseline MeS (0.75) to provide an overall absolute reduction in MeS and medication intensity of 0.25.

Secondary outcomes included weight and body composition assessed by bioelectrical impedance (InBody 230, InBody Co. Ltd. South Korea), fasting blood lipids (total cholesterol, triglycerides and HDL-cholesterol), glucose and insulin (Clinpath, Adelaide, Australia) with LDL-cholesterol calculated using the modified Friedewald equation \[[@CR31]\] and blood pressure was measured using an automated sphygmomanometer (SureSigns Vs3, Phillips Medical Systems, MA, USA); and physical activity levels assessed using seven consecutive days of ambulatory accelerometer monitoring (GT3X+; ActiGraph, Pensacola, FLA).

Continuous Glucose Monitoring, Glycaemic Variability and Medication Effect Score {#Sec6}
--------------------------------------------------------------------------------

Participants wore the Medtronic™ Guardian Connect^®^ device with the Harmony^®^ glucose sensor (Medtronic, Los Angeles, CA, USA) continuously for 13 weeks. All participants were blinded CGM for 1 week prior to commencement of the lifestyle intervention for baseline data collection, then randomisation revealed at baseline (week 0) for 12 weeks whilst following the lifestyle intervention. Devices were calibrated according to the manufacturer's recommendations with a sensor change every 10 days. Participants in the RT-CGM group received an iPod device (Apple iPod Nano, portable medial player, Cupertino, CA) which was Bluetooth connected to the CGM to provide real-time blood glucose level displays throughout the 12-week intervention period. All participants were asked to perform SMBG first thing in the morning before breakfast (fasting) and before each meal. Participants were provided with AccuChek™ glucometers (Roche Diagnostics, Sydney Australia) and testing strips, to replicate standard care.

Diurnal glucose profiles, derived from interstitial fluid readings performed every 5 min over back-to-back 10-day cycles for 91 days (i.e. 13 weeks), were collected using the CGM device. CGM data for the 7 days prior to intervention commencement and the final 7 days of the intervention were used as the pre- and post-study outcomes respectively to compute GV measures including mean, maximum and minimum glucose levels; standard deviation of glucose (SD~intraday~); mean amplitude of glycaemic excursions (MAGE); continuous overall net glycaemic action (CONGA-1, 2, 4 and 8); overall percentage of total time spent in euglycaemia (3.9--10 mmol/l), hyperglycaemia (\> 10.0 mmol/L) and hypoglycaemia (\< 3.9 mmol/L) were calculated as per glycaemic control targets described by the American Diabetes Association (ADA) \[[@CR2]\].

At baseline and throughout the study, blood sugar-lowering medication type, dosage and changes were monitored and documented. The anti-glycaemic MeS was calculated to assess overall utilisation of blood sugar-lowering medication, with higher MeS corresponding to higher usage of blood sugar-lowering medication \[[@CR28], [@CR29]\].

Statistical Analysis {#Sec7}
--------------------

Statistical analysis was conducted using SPSS Statistics 25 (IBM Corp, 2017). Analysis of covariance (ANCOVA) was used to test between-group differences at 12 weeks, using baseline measures as covariates \[[@CR32]\]. The model residuals were examined for normality and constant variance. Where these assumptions were not met, transformations of the variables were considered. Log (natural) transformation improved the distributional assumptions for serum LDL-C, GV indices and MeS, and*P* values from the transformed analyses are reported. Statistical significance was determined at *P* \< 0.05. Data are presented as mean ± SD.

Results {#Sec8}
=======

Twenty participants commenced and completed the study (Fig. [1](#Fig1){ref-type="fig"}). Baseline characteristics were similar between groups (mean ± SD; RT-CGM vs blinded CGM): age 60.2 ± 8.8 years vs. 60.9 ± 8.4 years, diabetes duration 10.5 ± 7.3 years vs. 11.0 ± 4.1 years, HbA1c 6.6 ± 0.9% vs. 7.1 ± 0.8% (49 ± 2 mmol/mol vs. 54 ± 2 mmol/mol) with an even gender distribution (5 men/5 women in both groups) (see Table S1 in the supplementary material).

Changes from baseline (mean ± SD) are reported in Table [1](#Tab1){ref-type="table"} (see supplementary material and Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} for changes in primary and secondary outcome profiles during the study and comparisons between treatments). After week 12, body weight, body fat, HbA1c, fasting glucose, insulin, blood lipids (total cholesterol, LDL-C, triglycerides and HDL-C) and blood pressure were not statistically different between groups (*P* ≥ 0.10).Table 2Changes in glycaemic variability profiles during the study and comparisons between treatmentsVariableRT-CGM (*n* = 8)Blinded CGM (*n* = 5)*P* value (ANCOVA)Baseline12 weeksChangeBaseline12 weeksChangeMean glucose minimum (mmol/L)4.24 ± 0.334.37 ± 0.900.13 ± 0.795.55 ± 0.434.388 ± 0.77− 1.17 ± 0.930.509Mean glucose maximum (mmol/L)11.70 ± 1.7811.25 ± 2.60− 0.45 ± 2.5513.49 ± 2.1711.50 ± 2.09− 1.99 ± 2.000.632Overall mean total glucose (mmol/L)7.00 ± 0.796.75 ± 1.21− 0.24 ± 0.878.70 ± 0.867.48 ± 1.45− 1.22 ± 1.370.413Standard deviation glucose (mmol/L)1.38 ± 0.521.29 ± 0.52− 0.07 ± 0.401.42 ± 0.361.47 ± 0.48− 0.06 ± 0.310.880Overall % time spent in Hypoglycemia (\< 3.9 mmol/L)0.01 ± 0.0180.26 ± 0.610.25 ± 0.610.00 ± 0.000.14 ± 0.3110.14 ± 0.310.630Overall % time spent in hyperglycemia (\> 10 mmol/L) (mmol/L)6.58 ± 8.687.09 ± 11.080.51 ± 7.8619.27 ± 13.7111.71 ± 18.29− 7.56 ± 14.150.139Overall % time spent in euglycaemia (3.9--10 mmol/L) (mmol/L)93.41 ± 8.6792.62 ± 11.15− 0.75 ± 7.4980.73 ± 13.7188.16 ± 18.207.42 ± 14.060.368Total analysed *n* = 13 (RT-CGM 8, blinded CGM 5). Missing glucose data due to device error or poor recording compliance. All values are mean ± SD unless otherwise stated*RT-CGM* real-time continuous glucose monitoring, *Blinded CGM* blinded continuous glucose monitoring Table 3Changes in glycaemic variability profiles for MAGE, CONGA-1, 2, 4 and 8 during the study and comparisons between treatmentsVariableRT-CGM (*n* = 9)Blinded CGM (*n* = 6)*P* value (ANCOVA)Baseline12 weeksChangeBaseline12 weeksChangeCONGA-1 (mmol/L)1.30 ± 0.361.03 ± 0.36− 0.27 ± 0.361.24 ± 0.411.30 ± 0.480.06 ± 0.190.074CONGA-2 (mmol/L)1.72 ± 0.511.36 ± 0.55− 0.36 ± 0.541.79 ± 0.6331.84 ± 0.770.05 ± 2.880.110CONGA-4 (mmol/L)2.02 ± 0.681.58 ± 0.75− 0.44 ± 0.672.18 ± 0.742.16 ± 0.93− 0.02 ± 0.420.186CONGA-8 (mmol/L)2.09 ± 0.681.73 ± 0.83− 0.36 ± 0.612.25 ± 0.732.22 ± 0.95− 0.02 ± 0.520.298MAGE (mmol/L)3.69 ± 1.083.01 ± 1.44− 0.69 ± 1.144.06 ± 1.234.05 ± 1.61− 0.09 ± 0.800.250Total analysed *n* = 15 (RT-CGM 9, blinded CGM 6). Missing glucose data due to device recording or sensor insertion error. All values are mean ± SD unless otherwise stated*RT-CGM* real-time continuous glucose monitoring, *Blinded CGM* blinded continuous glucose monitoring, *CONGA-1* continuous overall net glycaemic action of observations 1 h apart, *CONGA-2* continuous overall net glycaemic action of observations 2-h apart, *CONGA-4* continuous overall net glycaemic action of observations 4 h apart, *CONGA-8* continuous overall net glycaemic action of observations 8 h apart, *MAGE* mean amplitude of glycaemic excursions

Participants wore the CGM device for 84 consecutive days, with wear-time adherence at 100% for all but one participant who removed the device for aquatic activities for 3 days only. GV was assessed in 15 participants (RT-CGM, *n* = 9; blinded CGM, *n* = 6). Sufficient data, at week 12, were not collected for *n* = 5 participants secondary to reduced connectivity between glucose sensor and glucose recorder. No statistically significant differences between the groups at week 12 occurred for markers of GV including MAGE, CONGA-1, CONGA-8 and SD or anti-glycaemic MeS (*P* ≥ 0.11). Despite the lack of statistical significance, at week 12, GV indices were consistently 20--25% lower in the RT-CGM group compared with the blinded CGM group. Post hoc power analysis determined that a minimum of 35 participants per group would have been needed to achieve statistical significance. This was based on determining, for a parallel group superiority trial, the number of participants required in two randomised groups to have an 80% chance of detecting as significant at the 5% level the minimum difference between the groups means observed for the GV outcomes in the present study.

The level of diabetes medication, as reflected by the anti-glycaemic MeS, was 40% lower in the RT-CGM compared to the blinded CGM group at week 12. Thirteen participants had no change in anti-glycaemic MeS (RT-CGM, *n* = 7; blinded CGM, *n* = 6). In the RT-CGM group, three participants experienced a reduction in MeS with no participants experiencing an increase. In the blinded CGM group, two participants experienced a decrease in MeS and two participants experienced an increase.

Percentage time spent in sedentary behaviour and percentage time spent in moderate/vigorous activity were similar in both groups (*P* ≥ 0.11) at 12 weeks.

Discussion {#Sec9}
==========

This pilot study examined the effects of RT-CGM with visual feedback compared to blinded CGM, with no visual feedback in individuals with T2D when undertaking a low-intensity, prescriptive low-carbohydrate diet and lifestyle plan. Despite the apparent lack of statistical power, this study provides preliminary evidence that access to RT-CGM feedback is an effective approach to reinforce the effects of lifestyle modification strategies to improve diabetes control by reducing GV and diabetes medication requirements. The high level of device wear-time adherence also suggests a good tolerability to the device usage.

Overall, both groups achieved approximately 6% weight loss which is considered clinically relevant and comparable to most structured weight loss programmes that typically involve intensive counselling compared to this study that provided limited professional support \[[@CR4], [@CR33]\]. The lifestyle intervention in the present study used a low-carbohydrate-based prescriptive meal plan combined with a prescriptive aerobic/resistance-based exercise programme presented in a book format. This demonstrates that provision of a highly structured, prescriptive lifestyle plan can be an effective strategy to promote weight loss without the necessity of intensive professional support.

Together with weight loss, both groups experienced an average 0.7% HbA1c reduction. This is consistent with other weight loss studies in T2D of similar study duration \[[@CR20], [@CR23], [@CR34]\]. A recent meta-analysis demonstrated an estimated mean HbA1c reduction of 0.1% for each 1 kg of reduced body weight in this population \[[@CR35]\]. For every 1% reduction in HbA1c there is an expected 37% reduced risk for microvascular complications and 21% reduction in the risk of premature death related to T2D \[[@CR33]\]. This highlights the clinical significance of the changes observed in the present study.

Beyond HbA1c, which reflects average blood glucose levels over approximately 3 months, GV relates to fluctuations in blood glucose levels across the day or between days \[[@CR36], [@CR37]\]. GV has been identified as an independent risk factor of T2D-related micro- and macrovascular complications. Intermittent high blood glucose spikes, as opposed to constant exposure to high blood glucose, has been shown to promote damaging effects \[[@CR10], [@CR12], [@CR38]\]. Daily glucose fluctuations are incompletely expressed by HbA1c alone, particularly in patients considered to have good metabolic control or with prediabetes \[[@CR9], [@CR13], [@CR36], [@CR39], [@CR40]\]. To date, few studies have examined the effects of RT-CGM on GV. Yoo et al. demonstrated a 22% reduction in GV as measured by MAGE following the use of RT-CGM (worn for 3 days a month for 3 months) in 65 individuals with poorly controlled T2D (HbA1c \> 8%) \[[@CR20]\]. In this study no control group comparison was made. Similarly, in the present study, GV was approximately 20--25% lower in the RT-CGM compared to the blinded-CGM control after the intervention. However, as a result of the small sample size and lack of statistical significance, these data need to be interpreted with caution.

Nonetheless, these data suggest that RT-CGM may assist individuals to minimise blood glucose fluctuations and, given the emerging clinical importance of GV for promoting diabetes-related complications, larger studies are required to confirm these effects. A larger study could also investigate differences in the trajectories in the GV response over the intervention period. Additionally, since the individuals studied were in reasonable glycaemic control at baseline (mean HbA1c \< 7% and a high proportion of time spent in the euglycaemic range) this may have moderated the degree of improvement observed. Hence, further investigation of poorly controlled individuals that may experience more amplified improvements warrants further investigation. Larger future trials could use an intention to treat design and appropriate analysis to mitigate completer bias.

Despite commencing with a lower MeS, the RT-CGM group experienced a greater reduction in MeS compared to the blinded CGM group such that MeS was 40% lower in RT-CGM at week 12. However, it is important to note that these differential group changes were driven by medication changes in only a few individuals. Hence, these observations need to be treated with great caution. Nonetheless, despite the clinical benefits of intensive hypoglycaemic medication prescription for reducing macrovascular and microvascular disease risk through HbA1c reduction \[[@CR2]\], a recent report suggests that HbA1c reduction alone may not reduce macrovascular endpoints \[[@CR41], [@CR42]\] and the side effects of pharmacotherapy are well known \[[@CR43], [@CR44]\]. Thus it is necessary to examine the potential of RT-CGM to alter medication prescription in larger populations, particularly in highly medicated individuals.

It is well known that lifestyle therapies are effective in T2D management but adherence is difficult and that negatively impacts effectiveness \[[@CR15], [@CR40], [@CR45]\]. The preliminary data from the current study suggest that instant access to feedback regarding their daily glucose levels may improve patients' adherence and sustainability of lifestyle changes to optimise glucose control \[[@CR40], [@CR46]\]. This is supported by a recent systematic review providing robust evidence suggesting that engagement in self-management education had a most favourable effect on glycaemic control \[[@CR45]\]. However, debate exists on the duration and frequency of CGM data exposure that are required to modify behaviour and achieve clinically relevant improvements. Further studies should also examine the dose--response effect of exposure to RT-CGM data for the improvement of diabetes control.

The present study had several limitations. Firstly, this was a pilot study and, despite the promising magnitude of the differences observed between groups, results should be treated with caution and these promising results warrant further investigation with larger trials. The study also examined individuals with relatively good glycaemic control and future studies examining larger populations with wider levels of glucose control would allow a better understanding of the applicability of RT-CGM for T2D management. Additionally, evaluation of various drug types on markers of GV or MeS was not performed. Previous studies have demonstrated that an increase in oral hypoglycaemic medications may sometimes result in a drop in MAGE \[[@CR40]\]. To better understand the clinical implications of RT-CGM on GV, future trials should closely monitor and consider medication types, doses and changes in dose over the time course of the intervention. Some difficulties with device connectivity between sensor and recorder in the blinded CGM group were also experienced and future studies should specifically examine whether this is related to the blinded use of the CGM device. Finally, our retention rate was high, and it cannot be ruled out that provision of an honorarium, which is not reflective of current clinical practice, could have potentially influenced participant compliance to the intervention.

Conclusion {#Sec10}
==========

This study provides preliminary evidence that RT-CGM may enhance the benefits of a prescriptive low-carbohydrate diet and exercise plan delivered with minimal professional support, improving glycaemic control by reducing daily GV. These pilot findings provide a rationale for more comprehensive, larger-scale randomised controlled trials to be conducted. Trials should also consider the duration and frequency of sensor-wear time, medication types and changes in medication over longer-term interventions in order to better assess this therapeutic technology.
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